We appreciate the comments by Slow et al. (2011) on our article (Schwab et al., 2011) .
The principal aim of our study was to examine the long-term effects of betaine supplementation on the risk factors associated with the metabolic syndrome from the safety point of view (Schwab et al., 2011) . This is why we chose healthy subjects for this study. The title of our article referring to the risk factors associated with the metabolic syndrome can be judged to be somewhat misleading and we apologise for that. We have published data earlier on obese subjects with features of the metabolic syndrome. We found a decrease in plasma homocysteine concentration and an increase in serum total and low-density lipoprotein cholesterol concentrations during a hypocaloric diet (Schwab et al., 2002) .
We have also published data on the acute effect of betaine administration on plasma homocysteine concentrations in healthy subjects (Schwab et al., 2006) . A single dose of orally administered betaine had an acute and dose-dependent effect on serum betaine concentration and resulted in a decrease of plasma homocysteine concentration.
We agree with Drs Slow, Lever and Elmslie in that the effect of betaine seems to vary depending on the metabolic status of the subjects. We have unpublished data from subjects with the metabolic syndrome and plan to publish it in the near future.
